Chimeric Therapeutics Limited CHM
ASX · Australia · Health Technology
AUD 0.0030000.00 (0.00%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
The recent price decline of 18% in Chimeric Therapeutics Limited's ( ASX:CHM ) stock may have disappointed insiders who...
Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, today announced a 100% batch manufacturing and release success rate in support of Chimeric Therapeutics' CDH17-targeted autologous CAR-T program in Phase 1A/1B for gastrointestinal (GI) cancers, including colorectal and gastric cancer as we
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.